Cosentyx’s IL-17A mechanism provides a differentiated approach for HS in younger patients.
Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and includes its subsidiaries and/or associated companies) announced that the US ...
SALT LAKE CITY, UT, UNITED STATES, March 16, 2026 /EINPresswire.com/ -- The National Psoriasis Foundation (NPF) will ...
A new case study documents six months of complete pain relief in an 80-year-old man with arthritis, achieved without ...
The U.S. Food and Drug Administration has approved Deucravacitinib (Sotyktu) for the treatment of adults with Psoriatic Arthritis. This oral drug is a selective TYK2 inhibitor and had ...
ELV001 aiming to disrupt the treatment paradigm for patients with incomplete response to standard of care (methotrexate + TNF inhibitors)Phase 2b trial enrolling approximately 180 patients across nine ...
Patients with oncology, multiple sclerosis or inflammatory conditions such as irritable bowel syndrome, rheumatoid arthritis or dermatology were able to get their medications faster through an ...
If the sBLA is approved, expansion into psoriatic arthritis would build on the established clinical experience of ILUMYA as an IL-23 inhibitor for moderate-to-severe ...
Sun Pharmaceutical Industries Limited said on Monday, March 16, that the US Food and Drug Administration has accepted for review a supplemental Biologics License Application (sBLA) for ILUMYA.
A new weight-based secukinumab formulation provides a new option for treatment of adolescents with moderate-to-severe hidradenitis suppurativa (HS) with the FDA’s approval, according to a press ...
Rogers recommended gentle movement as a key component of managing chronic joint pain, cautioning against both overexertion ...
Some people online believe many of us have dangerous parasites in our gut and need to flush them out with herbal supplements.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results